DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies ...

In a recent study published in Cell, a research team led by Li Wei and Zhou Qi from the Institute of Zoology of the Chinese Academy of Sciences has developed an innovative gene-writing technology ...

Gene-editing technologies show great promise for medical treatments and research, with the potential to cure thousands of ...

Metagenomi announces successful integration of large genes in human cells using a novel, compact CAST system for potential therapeutic applications. Metagenomi, Inc., a precision genetic medicines ...

ElevateBio Life Edit (R) is the Company's gene editing technologies and R&D business, focused on building the world's largest gene editing toolbox to expand addressable diseases and open a new ...

Intellia is adopting a distinct strategy by focusing on in-vivo gene editing, potentially redefining industry standards and expectations. Interim results from Intellia's in-vivo gene-editing program ...

The UWA Tech & Policy Lab receives funding from nationally competitive research grants and philanthropic partners. The present research was supported by GA308883: Effective Ethical Frameworks for the ...

SAN FRANCISCO--(BUSINESS WIRE)--Kamau Therapeutics ("Kamau" or "the Company"), a clinical-stage gene correction company, announced today its emergence from stealth, following a strategic transaction ...

We know the genes, but not their functions—to resolve this long-standing bottleneck in microbial research, a joint research ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects for millions living with complex inherited diseases, such as cystic ...

Gene therapy is a revolutionary field in modern medicine, offering transformative potential to treat and potentially cure a wide range of genetic and acquired diseases. By addressing the root cause of ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced a ...